论文部分内容阅读
目的探讨厄贝沙坦对高血压合并心衰患者的超敏C反应蛋白(hs-CRP)、B型脑钠肽(BNP)的影响。方法选取高血压合并心力衰竭患者80例,按照数字随机法分为两组,每组40例。所有患者均实施严格卧床、吸氧、降压、强心、利尿、扩血管等治疗,对照组加用卡托普利,观察组加用厄贝沙坦,均连续治疗1周。比较两组患者治疗前后hs-CRP及BNP的变化,并统计治疗期间两组出现的不良反应。结果观察组显效率为80.0%,显著高于对照组的35.0%,差异有统计学意义(P<0.05);治疗后两组hs-CRP和BNP水平低于治疗前(P<0.05),且治疗后观察组hs-CRP和BNP水平低于对照组(P<0.05);观察组咳嗽发生率低于对照组(P<0.05),两组口干和头晕发生率差异无统计学意义(P>0.05)。结论厄贝沙坦治疗高血压合并心力衰竭患者,能迅速降低机体炎症反应,改善心肌功能,且其使用后咳嗽等不良反应明显减少,值得临床推广。
Objective To investigate the effects of irbesartan on high-sensitivity C-reactive protein (hs-CRP) and brain natriuretic peptide (BNP) in patients with hypertension and heart failure. Methods Eighty patients with hypertension and heart failure were selected and divided into two groups according to the number randomization method, 40 cases in each group. All patients were strictly bedridden, oxygen, blood pressure, cardiac, diuretic, vasodilator and other treatment, the control group plus captopril, the observation group plus irbesartan, were treated for 1 week. The changes of hs-CRP and BNP before and after treatment were compared between the two groups, and the adverse reactions in both groups were statistically analyzed. Results The effective rate of observation group was 80.0%, which was significantly higher than that of control group (35.0%) (P <0.05). The levels of hs-CRP and BNP in two groups after treatment were lower than those before treatment (P <0.05) After treatment, the levels of hs-CRP and BNP in the observation group were lower than those in the control group (P <0.05). The incidence of cough in the observation group was lower than that in the control group (P <0.05), and there was no significant difference in the incidence of dry mouth and dizziness > 0.05). Conclusion Irbesartan treatment of patients with hypertension complicated with heart failure can rapidly reduce the body inflammatory response and improve myocardial function, and its use of cough and other adverse reactions was significantly reduced, worthy of clinical promotion.